Harrow Health Inc (HROW) - Total Liabilities
Based on the latest financial reports, Harrow Health Inc (HROW) has total liabilities worth $401.97 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Harrow Health Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Harrow Health Inc - Total Liabilities Trend (2005–2025)
This chart illustrates how Harrow Health Inc's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Harrow Health Inc to evaluate the company's liquid asset resilience ratio.
Harrow Health Inc Competitors by Total Liabilities
The table below lists competitors of Harrow Health Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yubico AB
ST:YUBICO
|
Sweden | Skr589.70 Million |
|
Oriental Holdings Bhd
KLSE:4006
|
Malaysia | RM4.19 Billion |
|
Platinum Asset Management Ltd
AU:PTM
|
Australia | AU$37.54 Million |
|
Sam Hwa Capaci
KO:001820
|
Korea | ₩58.96 Billion |
|
Jastrzebska Spotka Weglowa SA
WAR:JSW
|
Poland | zł10.75 Billion |
|
Ecovyst Inc
NYSE:ECVT
|
USA | $833.80 Million |
|
Cymbria Corporation
TO:CYB
|
Canada | CA$138.94 Million |
|
Icade SA
PA:ICAD
|
France | €5.37 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Harrow Health Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Harrow Health Inc asset portfolio.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 26.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.96 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Harrow Health Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Harrow Health Inc (2005–2025)
The table below shows the annual total liabilities of Harrow Health Inc from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $347.39 Million | +8.67% |
| 2024-12-31 | $319.67 Million | +32.23% |
| 2023-12-31 | $241.75 Million | +85.77% |
| 2022-12-31 | $130.14 Million | +48.90% |
| 2021-12-31 | $87.40 Million | +185.19% |
| 2020-12-31 | $30.65 Million | -3.22% |
| 2019-12-31 | $31.67 Million | +28.21% |
| 2018-12-31 | $24.70 Million | +15.95% |
| 2017-12-31 | $21.30 Million | +2.34% |
| 2016-12-31 | $20.82 Million | +34.15% |
| 2015-12-31 | $15.52 Million | +641.66% |
| 2014-12-31 | $2.09 Million | +221.54% |
| 2013-12-31 | $650.63K | -8.31% |
| 2012-12-31 | $709.56K | -61.87% |
| 2011-12-31 | $1.86 Million | +33.83% |
| 2010-12-31 | $1.39 Million | +27.00% |
| 2009-12-31 | $1.09 Million | +43.31% |
| 2008-12-31 | $763.99K | +1.83% |
| 2007-12-31 | $750.24K | +19236.11% |
| 2006-12-31 | $3.88K | -21.62% |
| 2005-12-31 | $4.95K | -- |
About Harrow Health Inc
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, in… Read more